Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial.
暂无分享,去创建一个
M. Mack | G. Stone | B. Whisenant | W. Abraham | S. Arnold | D. Cohen | M. Rinaldi | E. Magnuson | J. Lindenfeld | A. Brieke | A. Asgar | S. Baron | Kaijun Wang | D. Cohen
[1] S. Baron. Clinical Trial Perspective: Cost-effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation. Results From the COAPT Trial , 2020 .
[2] M. Mack,et al. Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. , 2019, Journal of the American College of Cardiology.
[3] A. Sannino,et al. Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.
[4] R. Bonow,et al. Percutaneous Repair of Secondary Mitral Regurgitation - A Tale of Two Trials. , 2018, The New England journal of medicine.
[5] M. Mack,et al. Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.
[6] D. Maucort-Boulch,et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.
[7] A. Sannino,et al. Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation: A Systematic Review and Meta-analysis , 2017, JAMA cardiology.
[8] M. Claeys,et al. Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection Fraction. , 2017, JACC. Heart failure.
[9] E. Arias,et al. United States Life Tables, 2014. , 2017, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[10] M. Gold,et al. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. , 2017, JACC. Heart failure.
[11] A. Ducharme,et al. Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients , 2017, Journal of medical economics.
[12] Jagmeet P. Singh,et al. Impact of cardiac resynchronization therapy on mitral valve apparatus geometry and clinical outcomes in patients with secondary mitral regurgitation , 2017, Echocardiography.
[13] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[14] D. Adams,et al. Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.
[15] G. Fonarow,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Circulation.
[16] T. Feldman,et al. EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery , 2013, Journal of medical economics.
[17] A. Moss,et al. Cost‐Effectiveness of Cardiac Resynchronization Therapy in the MADIT‐CRT Trial , 2013, Journal of cardiovascular electrophysiology.
[18] W. O’Neill,et al. Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis: Results From the Placement of Aortic Transcatheter Valves (PARTNER) Trial (Cohort B) , 2012, Circulation.
[19] M. Slaughter,et al. Cost-Effectiveness Analysis of Continuous-Flow Left Ventricular Assist Devices as Destination Therapy , 2012, Circulation. Heart failure.
[20] A. Owen. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2005, European heart journal.
[21] Douglas K Owens,et al. Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.
[22] S. Bolling,et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. , 2005, Journal of the American College of Cardiology.
[23] J. Brazier,et al. The Estimation of a Preference-Based Measure of Health From the SF-12 , 2004, Medical care.
[24] Liming Cai,et al. Health, life expectancy, and health care spending among the elderly. , 2003, The New England journal of medicine.
[25] Anastasios A. Tsiatis,et al. Estimating medical costs with censored data , 2000 .
[26] B. Efron. Better Bootstrap Confidence Intervals , 1987 .
[27] J. Gorman,et al. Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.
[28] J. Daubert,et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2006, European heart journal.